This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / Alto Neuroscience Securities Fraud Lawsuit
Regulatory securities lawsuit

Alto Neuroscience Securities Fraud Lawsuit

Analysis based on 7 articles · First reported Jul 29, 2025 · Last updated Sep 03, 2025

Sentiment
-70
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted by the news of Alto Neuroscience's failed drug trial, leading to a significant drop in its stock price. The ongoing securities lawsuit against Alto Neuroscience creates uncertainty for investors and highlights the risks associated with pharmaceutical development.

Biotechnology Legal Services
Event Summary

Alto Neuroscience is facing a federal securities class action lawsuit filed by Faruqi & Faruqi. The lawsuit alleges that Alto Neuroscience and its executives made false and misleading statements regarding the effectiveness and commercial prospects of its drug ALTO-100, intended for treating Major Depressive Disorder (MDD). On October 22, 2024, Alto Neuroscience announced that ALTO-100 failed to meet its primary endpoint in a Phase 2b trial, causing its stock price to plummet by nearly 70%. Analysts, including Jefferies, subsequently cut their price targets for Alto Neuroscience, raising concerns about the company's overall biomarker approach to CNS disorders. Investors who purchased Alto Neuroscience stock between February 2, 2024, and October 22, 2024, are encouraged to join the class action lawsuit, with a deadline of September 19, 2025, to seek the role of lead plaintiff.

Entities Involved
stock
Alto Neuroscience
Alto Neuroscience is facing a federal securities class action lawsuit due to allegedly misleading statements regarding the effectiveness of its drug ALTO-100 for MDD, which led to a significant drop in its stock price.
Importance 100.0 Sentiment -80.0
priv
Jefferies
Jefferies cut its price target for Alto Neuroscience after the negative ALTO-100 trial results, raising questions about the company's biomarker approach.
Importance 30.0 Sentiment 0.0
per
James Wilson
Importance 0.0 Sentiment 0.0
priv
Faruqi & Faruqi
Importance 0.0 Sentiment 0.0
Relationships
James Wilson partner ↔ Faruqi & Faruqi James Wilson is a partner at the national securities law firm Faruqi & Faruqi, LLP, where he actively represents the fir
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.